Filter Results
:
(185)
Show Results For
-
All HBS Web
(308)
- People (1)
- News (81)
- Research (185)
- Multimedia (3)
- Faculty Publications (123)
Show Results For
-
All HBS Web
(308)
- People (1)
- News (81)
- Research (185)
- Multimedia (3)
- Faculty Publications (123)
Sort by
- 02 Jul 2001
- Research & Ideas
Ray A. Goldberg
issues," he beams, "from land reform in Mexico to the development of the genetically modified tomato." "The genetic research revolution is changing our global economy and society more...
View Details
- 15 Jan 2018
- Research & Ideas
A Better Business Model for Fighting Cancer
question—it’s clear.” Simply put, inefficiencies in the development of precision medicine can best be addressed by a business-analysis approach. With the mapping of the human genome completed 15 years ago, the sci-fi concept of using a cancer patient’s View Details
- February 2008 (Revised August 2008)
- Case
EXACT Sciences Corp.: Commercializing a Diagnostic Test
This case addresses the challenges of commercializing molecular diagnostics. Along the way, it explains the technology, payment system, and the measures used to assess the value of a diagnostic test.
View Details
Keywords:
Health Testing and Trials;
Genetics;
Science-Based Business;
Commercialization;
Biotechnology Industry
Herzlinger, Regina E. "EXACT Sciences Corp.: Commercializing a Diagnostic Test." Harvard Business School Case 308-090, February 2008. (Revised August 2008.)
- October 2011
- Case
Gene Sequencing: Staking a Position in an Expanding Industry
By: Richard G. Hamermesh, Mara Aspinall and Phillip Andrews
Towards the end of 2010, companies in the gene sequencing industry were pushing aggressive R&D programs to develop technologies and products in the race to sequence the entire human genome at a cost of $1,000. It remained to be seen when the "$1,000 genome" would...
View Details
Keywords:
Genetics;
Business Growth and Maturation;
Business Plan;
Competition;
Venture Capital;
Biotechnology Industry
Hamermesh, Richard G., Mara Aspinall, and Phillip Andrews. "Gene Sequencing: Staking a Position in an Expanding Industry." Harvard Business School Case 812-004, October 2011.
- June 1997 (Revised September 1997)
- Case
Genset Initial Public Offering (B)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Supplements the (A) case.
View Details
Keywords:
Business Model;
Initial Public Offering;
Genetics;
Going Public;
Management Teams;
Biotechnology Industry;
France;
United States
Gompers, Paul A., and Jeffrey M. Anapolsky. "Genset Initial Public Offering (B)." Harvard Business School Case 297-097, June 1997. (Revised September 1997.)
- June 1997 (Revised March 2001)
- Case
Genset Initial Public Offering (A)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Pascal Brandys, founder and CEO of Genset, must decide whether to take this young biotechnology company public. If so, should he do a dual offering in both France and the U.S.? The case also explores the business models in genomics research.
View Details
Keywords:
Business Model;
Initial Public Offering;
Genetics;
Going Public;
Management Teams;
Biotechnology Industry;
France;
United States
Gompers, Paul A., and Jeffrey M. Anapolsky. "Genset Initial Public Offering (A)." Harvard Business School Case 297-096, June 1997. (Revised March 2001.)
- 24 Jan 2005
- Research & Ideas
Entrepreneurial Hospital Pioneers New Model
But what's more interesting—and this is a function of operating in an environment such as India where heart disease is endemic—it's a genetic trait among Indians, and also there are so many people, so there are more heart ailments—is that...
View Details
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
genetically modified foods in Europe. Betting the company on a "life sciences" vision, Shapiro had sold or spun off Monsanto's traditional chemical businesses and moved aggressively to acquire seed companies. Dazzled by the...
View Details
Keywords:
by Michael D. Watkins & Max H. Bazerman
- 27 Mar 2012
- First Look
First Look: March 27
find emissions to be less under cap-and-trade, with technology choice driving the vast majority of the difference. Download the paper: http://www.hbs.edu/research/pdf/12-079.pdf Lords of the Harvest: Third-Party Signaling and Regulatory Approval of View Details
Keywords:
Carmen Nobel
- 12 Nov 2015
- Research & Ideas
Can Consumers be Trusted with Their Own Health Care?
reveals a person’s genetically based health risk across dozens of disease categories. 23andMe test results showed one patient at higher risk of liver and bowel cancer—and that made sense, given family history. The patient discussed the...
View Details
- 05 Dec 2013
- Op-Ed
Encourage Breakthrough Health Care by Competing on Products Rather Than Patents
Like many people interested in the tangled connections between health care progress and intellectual property rights, I avidly followed the Myriad Genetics case, decided by the Supreme Court this June 13. In sum, molecular diagnostics...
View Details
- October 2010 (Revised November 2010)
- Background Note
Plavix: Drugs in the Age of Personalized Medicine
By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon
PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon, and recently new data had been discovered that indicated that a small subset of the population would be at risk for stroke, heart attack, or even...
View Details
Keywords:
Health Care and Treatment;
Product Positioning;
Business and Government Relations;
Genetics;
Competitive Strategy;
Pharmaceutical Industry
Hamermesh, Richard G., Mara G. Aspinall, and Rachel Gordon. "Plavix: Drugs in the Age of Personalized Medicine." Harvard Business School Background Note 811-001, October 2010. (Revised November 2010.)
- 14 Jul 2009
- First Look
First Look: July 14
Course MaterialsThe DiagnoFirst Opportunity Harvard Business School Case 309-112 John Mason, a principle at Oldwell Partners, was facing a decision of whether or not to invest in DiagnoFirst, a molecular diagnostics firm. DiagnoFirst's key product was a View Details
Keywords:
Martha Lagace
- October 2001 (Revised March 2008)
- Case
Anagene, Inc.
By: Robert S. Kaplan and Christina L. Darwall
An entrepreneurial, publicly traded biotech company has begun production and sales of its core product--cartridges that permit DNA samples to be analyzed on a microchip. In the early quarters, sales are difficult to forecast and the company has experienced fluctuating...
View Details
Keywords:
Cost Accounting;
Financial Reporting;
Production;
Performance Capacity;
Risk and Uncertainty;
Genetics;
Governing and Advisory Boards;
Biotechnology Industry;
California
Kaplan, Robert S., and Christina L. Darwall. "Anagene, Inc." Harvard Business School Case 102-030, October 2001. (Revised March 2008.)
- 03 Mar 2015
- First Look
First Look: March 3
a lower price but charge more for the cartridges necessary to run a sample and earn its primary revenue from these cartridges. The third model would see GenapSys sell its device at or around cost, but use the data customers generated to create a proprietary database of...
View Details
Keywords:
Sean Silverthorne
- June 2011 (Revised October 2013)
- Case
Gene Patents (A)
By: Richard Hamermesh, David Kiron and Phillip Andrews
In March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues...
View Details
Keywords:
Courts and Trials;
Patents;
Genetics;
Judgments;
Science-Based Business;
Biotechnology Industry;
United States
Hamermesh, Richard, David Kiron, and Phillip Andrews. "Gene Patents (A)." Harvard Business School Case 811-089, June 2011. (Revised October 2013.)
- January 2009 (Revised July 2010)
- Case
iZumi
By: Robert F. Higgins, Jacob Ian Broder-Fingert, Eliot Sherman and Sidhartha Palani
Presents the issues faced while building an innovative company in an emerging space with new intellectual property from the perspective of a venture capitalist. Beth Seidenberg, a partner at the venture capital firm Kleiner Perkins Caufield & Byers (KPCB), had helped...
View Details
- 20 Nov 2012
- First Look
First Look: November 20
and Regulatory Approval of Genetically Modified Organisms Authors:Shon R. Hiatt and Sangchan Park Publication:Academy of Management Journal (forthcoming) Abstract Little is known about the factors that influence regulatory-agency decision...
View Details
Keywords:
Sean Silverthorne
- November 2006 (Revised March 2008)
- Case
The Harvard Stem Cell Institute
Describes a set of issues confronting the leaders of the Harvard Stem Cell Institute, an innovative cross-university effort to accelerate scientific discovery and translation in the domain of stem cells. Covers a wide range of topics, including understanding how...
View Details
Keywords:
Talent and Talent Management;
Higher Education;
Entrepreneurship;
Collaborative Innovation and Invention;
Intellectual Property;
Research and Development;
Genetics;
Biotechnology Industry;
Health Industry;
Massachusetts
Sahlman, William A. "The Harvard Stem Cell Institute." Harvard Business School Case 807-096, November 2006. (Revised March 2008.)
- 12 Aug 2008
- First Look
First Look: August 12, 2008
Commercializing a Diagnostic Test Harvard Business School Case 308-090 What are the barriers and opportunities to commercializing genetic diagnoses for disease? Purchase the case:...
View Details
Keywords:
Sean Silverthorne